Medipost and U.S. Stem Cell Inc. – Significant Players in Stem cell therapy Market
Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery.
Market leaders operating in the market have undertaken various organic growth strategies in the stem cell therapy market. The stem cell therapy market majorly consists of the players such as Medipost, pharmicell Co., Ltd., Holostem Terapie Avanzate S.R.L., Mesoblast Ltd., U.S. Stem Cell, Inc., Biotime, Inc., RichSource, Caladrius, TiGenix NV (Takeda Pharmaceuticals), Genea Biocells, and among others. Several organic approaches, such as product launches, and expansion/relocation in the stem cell therapy market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the stem cell therapy market:
|
Year |
News |
|
Aug-2018 |
RichSource introduced new product line Richgen. The newly launched product can be utilized to treat various diseases such as cancer, diabetes, Lyme’s disease, asthma, and neuropathy and joint pain. Moreover, the product is also recommended for topical wound healing. |
|
Feb-2018 |
Holostem Terapie Avanzate Srl got Europe approval for its first stem cell therapy product Holoclar. The medicinal product is highly recommended to restore the eyesight of patients with severe cornea damage. |
|
Dec-2018 |
U.S. Stem Cell Inc, a significant player in regenerative medicine products and services, announced its strategic plan to expand Florida-based stem cell clinics to meet the growing market demand and patient needs for regenerative therapies. |
|
Dec- 2019 |
The partnership of Lineage Cell Therapeutics and AgeX Therapeutics registered US patent for method of generating induced pluripotent stem cells. |
|
Jun-2018 |
The partnership of Holostem and Chiesi got FDA Orphan Drug Designation for its GPLSCD01 product. The product is recommended for the treatment of Limbal Stem Cell Deficiency (LSCD). |
